The charts of 1869 @entity1 were reviewed for the occurrence of @entity1150 ( @entity1150 ) and @entity1151 after total hip or knee arthroplasty. Prophylaxis consisted of 3 (group 1; n=1235) or 6 (group 2; n=634) weeks low-dose @entity1229 , pneumatic compression boots worn by @entity1 in the hospital, mobilization on the first postoperative day, and a clinical surveillance protocol. Venous ultrasound or ventilation/perfusion lung scintigraphy (V/Q) was performed only if @entity1 became symptomatic. @entity1 . Twenty-three (1.8%) @entity1 were positive for @entity1150 . Ventilation/perfusion lung scintigraphy was performed on 25 @entity1 , and 5 (0.4%) @entity1 were positive for @entity1151 . In group 2, 117 @entity1 were evaluated for @entity1150 , and 19 (3%) @entity1 had positive results determined by ultrasound. Twenty-five @entity1 were evaluated with V/Q and only 1 (0.16%) @entity1 was positive for @entity1151 . No @entity1 developed a fatal @entity1151 or @entity5226 . This prophylaxis protocol is an efficient and cost-effective method for the prevention of significant events after surgery.

Safety of a clinical surveillance protocol with 3- and 6-week XXXX prophylaxis after total joint arthroplasty.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis', 'DVT'] @entity5226 :: ('MESH:D011186', 'Disease') :: ['postphlebitic syndrome'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity1229 :: (MESH:D014859,Chemical) :: ['warfarin']
